This dual effect underscores that APOC3 modulation differentially affects circulating triglyceride metabolism and hepatic lipogenesis, supporting therapeutic strategies that combine APOC3 inhibition with insulin-sensitizing or steatosis-targeting agents to disrupt the vicious cycle of hypertriglyceridemia and fatty liver. This evidence concerns the gene INS and steatosis.